Denmark’s Lundbeck is set to acquire Longboard Pharmaceuticals for about $2.5 billion. California-based Longboard has a small molecule, bexicaserin, in late-stage clinical trials for certain ...

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion ...

Lundbeck announced this week that it will acquire Longboard Pharmaceuticals in a $2.6 billion deal, picking up the epilepsy drug bexicaserin in the process. The move — the largest to date for the ...

Lundbeck’s acquisition of Longboard Pharmaceuticals aims to bolster its neuro-rare conditions portfolio with the addition of bexicaserin. Credit: UnderhilStudio ...

Oct 14 (Reuters) - H Lundbeck A/S (HLUNb.CO), opens new tab has agreed to buy U.S.-based Longboard Pharmaceuticals (LBPH.O), opens new tab for $2.6 billion, marking the biggest deal ever by the ...

Shares of Longboard Pharmaceuticals Inc. are surging more than 51% Monday, boosted by H. Lundbeck’s $2.6 billion deal to acquire the California-based clinical-stage biopharmaceutical company.

(RTTNews) - Danish pharmaceutical company H. Lundbeck A/S (HLUKY.PK, HLUKF.PK) and Longboard Pharmaceuticals, Inc. (LBPH), announced Monday an agreement for Lundbeck to acquire Longboard $60 per ...

VALBY, Denmark & LA JOLLA, Calif.--(BUSINESS WIRE)--H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc (NASDAQ: LBPH) (Longboard) today announced an agreement for Lundbeck to acquire ...

Danish pharmaceutical company Lundbeck will buy Longboard Pharmaceuticals (LBPH) in a deal valued at $2.6 billion, with the former hoping to build off of its pipeline of epilepsy drug treatment.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...